Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 13,967,000 | 11,939,000 | 8,572,000 | 6,049,000 | 24,018,000 |
| Depreciation Amortization | 5,275,000 | 6,114,000 | 8,383,000 | 6,965,000 | N/A |
| Income taxes - deferred | 2,385,000 | 1,701,000 | 551,000 | 1,128,000 | N/A |
| Accounts receivable | -1,124,000 | -931,000 | -1,504,000 | N/A | -389,000 |
| Accounts payable and accrued liabilities | -273,000 | -105,000 | 479,000 | N/A | -21,000 |
| Other Working Capital | -1,577,000 | -706,000 | -369,000 | -796,000 | 241,000 |
| Other Operating Activity | 491,000 | -393,000 | -1,654,000 | 890,000 | -8,778,000 |
| Operating Cash Flow | $19,144,000 | $17,619,000 | $14,458,000 | $14,236,000 | $15,071,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 1,781,000 | -711,000 | 10,607,000 | 4,662,000 | -14,105,000 |
| PPE Investments | -1,535,000 | -1,280,000 | -823,000 | -758,000 | -1,138,000 |
| Net Acquisitions | -235,000 | -3,911,000 | -4,681,000 | -1,276,000 | 20,102,000 |
| Purchase Of Investment | -116,000 | -193,000 | -117,000 | -139,000 | -191,000 |
| Sale Of Investment | 209,000 | 957,000 | 348,000 | 133,000 | 442,000 |
| Purchase Sale Intangibles | -2,188,000 | -2,368,000 | 262,000 | -1,153,000 | -845,000 |
| Other Investing Activity | -4,981,000 | -2,375,000 | 262,000 | -1,154,000 | -902,000 |
| Investing Cash Flow | $-4,877,000 | $-7,513,000 | $5,596,000 | $1,468,000 | $4,208,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 5,000 | 958,000 | 546,000 | 252,000 | -3,524,000 |
| Debt Issued | 6,098,000 | 6,143,000 | N/A | N/A | 16,000 |
| Debt Repayment | N/A | -289,000 | -2,223,000 | -2,575,000 | -2,162,000 |
| Common Stock Issued | 27,000 | 30,000 | 153,000 | 100,000 | 53,000 |
| Common Stock Repurchased | -9,212,000 | -8,331,000 | -8,719,000 | -10,652,000 | -3,057,000 |
| Dividend Paid | -7,818,000 | -7,624,000 | -7,255,000 | -7,506,000 | -7,368,000 |
| Other Financing Activity | -3,967,000 | -2,629,000 | 3,220,000 | -181,000 | -222,000 |
| Financing Cash Flow | $-14,867,000 | $-11,742,000 | $-14,278,000 | $-20,562,000 | $-16,264,000 |
| Exchange Rate Effect | 576,000 | -298,000 | 100,000 | -32,000 | -266,000 |
| Beginning Cash Position | 11,459,000 | 13,393,000 | 7,517,000 | 12,407,000 | 9,658,000 |
| End Cash Position | 11,435,000 | 11,459,000 | 13,393,000 | 7,517,000 | 12,407,000 |
| Net Cash Flow | $-24,000 | $-1,934,000 | $5,876,000 | $-4,890,000 | $2,749,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 19,144,000 | 17,619,000 | 14,458,000 | 14,236,000 | 15,071,000 |
| Capital Expenditure | -1,548,000 | -1,366,000 | -1,060,000 | -916,000 | -1,378,000 |
| Free Cash Flow | 17,596,000 | 16,253,000 | 13,398,000 | 13,320,000 | 13,693,000 |